{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:28:06Z","timestamp":1753892886631,"version":"3.41.2"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Background and aim<\/jats:title><jats:p>Chronic hepatitis B (CHB) can be divided into immune tolerance (IT), immune clearance (IC), hepatitis B e antigen (HBeAg)-negative inactive\/quiescent carrier (ENQ), and HBeAg-negative hepatitis (ENH) phases. The conventional biomarkers used to distinguish these phases have limitations. We examined the clinical significance of hepatitis B virus (HBV) RNA and hepatitis B core-related antigen (HBcrAg) as novel biomarkers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>One hundred eighty-nine patients without treatment currently were categorized by CHB phase (IT = 46, IC = 45, ENQ = 49, ENH = 49). The associations of HBV RNA and HBcrAg with HBV DNA and alanine transaminase (ALT) were analyzed. The decision tree model was used to distinguish the four phases in the natural course of CHB.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The concentrations of HBV RNA and HBcrAg were highest in the IT and IC phases (<jats:italic>P<\/jats:italic> &amp;lt; 0.01). Serum HBV RNA was similar to HBcrAg in treatment-na\u00efve patients. HBV RNA and HBcrAg correlated with HBV DNA in the HBeAg<jats:sup>+<\/jats:sup> and HBeAg<jats:sup>\u2212<\/jats:sup> status (HBV RNA: e<jats:sup>+<\/jats:sup> r = 0.51, e<jats:sup>\u2212<\/jats:sup> r = 0.62; HBcrAg: e<jats:sup>+<\/jats:sup> r = 0.51, e<jats:sup>\u2212<\/jats:sup> r = 0.71), but their association with HBV DNA differed among phases. The accuracy, sensitivity, and specificity of HBcrAg with ALT in distinguishing the CHB phases were 95.65%, 95.83%, and 95.55%, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Serum HBV RNA and HBcrAg may be useful to monitor CHB progression.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2022.1037508","type":"journal-article","created":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T10:00:06Z","timestamp":1666951206000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical significance of novel biomarkers to predict the natural course of hepatitis B infection"],"prefix":"10.3389","volume":"10","author":[{"given":"Weikang","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojie","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weilu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haowei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangyu","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenling","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunhui","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haitao","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengmei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yancheng","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongjun","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaohua","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,28]]},"reference":[{"key":"B1","unstructured":"World Health OrganizationHepatitis B2022"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology."},{"key":"B3","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int."},{"key":"B5","doi-asserted-by":"publisher","first-page":"769","DOI":"10.14218\/JCTH.2021.00209","article-title":"Guidelines for Prevention and Treatment of Chronic Hepatitis B","volume":"9","author":"Wang","year":"2021","journal-title":"J Clin Transl Hepatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/jvh.12643","article-title":"Determination of hepatitis B phenotype using biochemical and serological markers","volume":"24","author":"Di Bisceglie","year":"2017","journal-title":"J Viral Hepat."},{"key":"B7","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s12072-012-9365-4","article-title":"Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update","volume":"6","author":"Liaw","year":"2012","journal-title":"Hepatol Int."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e78672","DOI":"10.1371\/journal.pone.0078672","article-title":"Significant fibrosis is not rare in Chinese chronic hepatitis B patients with persistent normal ALT","volume":"8","author":"Liao","year":"2013","journal-title":"PLoS ONE."},{"key":"B9","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1365-2893.2010.01270.x","article-title":"Significant histopathology in Chinese chronic hepatitis B patients with persistently high-normal alanine aminotransferase","volume":"17","author":"Gui","year":"2010","journal-title":"J Viral Hepat."},{"key":"B10","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1002\/hep.32018","article-title":"Comparison of HBV RNA and Hepatitis B core related antigen with conventional HBV markers among untreated adults with chronic hepatitis B in North America","volume":"74","author":"Ghany","year":"2021","journal-title":"Hepatology."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1002\/hep.31616","article-title":"HBV RNA profiles in patients with chronic hepatitis b under different disease phases and antiviral therapy","volume":"73","author":"Mak","year":"2021","journal-title":"Hepatology."},{"key":"B13","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1111\/jvh.13299","article-title":"HBcrAg and pg RNA and the therapeutic effect in HBeAg-positive patients receiving anti-viral therapy, baseline serum HBV-RNA is a powerful predictor of response","volume":"27","author":"Ma","year":"2020","journal-title":"J Viral Hepat."},{"key":"B14","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.jhep.2016.05.029","article-title":"Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound","volume":"65","author":"Wang","year":"2016","journal-title":"J Hepatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1002\/hep.30325","article-title":"Serum hepatitis B virus RNA: a new potential biomarker for chronic hepatitis B virus infection","volume":"69","author":"Liu","year":"2019","journal-title":"Hepatology."},{"key":"B16","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1111\/liv.13346","article-title":"Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA","volume":"37","author":"Wong","year":"2017","journal-title":"Liver Int."},{"key":"B17","doi-asserted-by":"publisher","first-page":"606.e1","DOI":"10.1016\/j.cmi.2015.02.010","article-title":"Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D","volume":"21","author":"Maasoumy","year":"2015","journal-title":"Clin Microbiol Infect."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1111\/1469-0691.12739","article-title":"Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B","volume":"20","author":"Seto","year":"2014","journal-title":"Clin Microbiol Infect."},{"key":"B19","unstructured":"KuhnM\n            WingJ\n            WestonS\n            WilliamsA\n            KeeferC\n            EngelhardtA\n          Caret: Classification Regression Training.2022"},{"key":"B20","unstructured":"TherneauT\n            RipleyB\n          rpart: Recursive Partitioning Regression Trees.2022"},{"key":"B21","unstructured":"MilborrowS\n          rpart.plot: Plot \u2018rpart' Models: An Enhanced Version of \u2018plot.rpart'.2022"},{"key":"B22","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12876-019-0966-4","article-title":"Serum HBV RNA quantification: useful for monitoring natural history of chronic hepatitis B infection","volume":"19","author":"Liu","year":"2019","journal-title":"BMC Gastroenterol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1111\/jvh.12908","article-title":"Natural history of serum HBV-RNA in chronic HBV infection","volume":"25","author":"Wang","year":"2018","journal-title":"J Viral Hepat."},{"key":"B24","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12985-018-0994-7","article-title":"High serum levels of pregenomic RNA reflect frequently failing reverse transcription in hepatitis B virus particles","volume":"15","author":"Prakash","year":"2018","journal-title":"Virol J."},{"key":"B25","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/hep.31026","article-title":"Pregenomic HBV RNA and hepatitis B core-related antigen predict outcomes in hepatitis B e antigen-negative chronic hepatitis b patients suppressed on Nucleos(T)ide analogue therapy","volume":"72","author":"Carey","year":"2020","journal-title":"Hepatology."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1002\/hep.30082","article-title":"Hepatitis B virus serum DNA andRNA levels in Nucleos(t)ide analog-treated or untreated patients during chronic and acute infection","volume":"68","author":"Butler","year":"2018","journal-title":"Hepatology."},{"key":"B27","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1136\/gutjnl-2011-301096","article-title":"Quantification of serum hepatitis B surface antigen: is it useful for the management of chronic hepatitis B?","volume":"61","author":"Janssen","year":"2012","journal-title":"Gut."},{"key":"B28","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.cld.2013.05.006","article-title":"HBsAg quantification to predict natural history and treatment outcome in chronic hepatitis B patients","volume":"17","author":"Martinot-Peignoux","year":"2013","journal-title":"Clin Liver Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/jvh.12805","article-title":"Prevalence and natural course of occult hepatitis B virus infection in residents of 2 communities of Wuwei City, Gansu Province, China","volume":"25","author":"Wen","year":"2018","journal-title":"J Viral Hepat."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.7754\/Clin.Lab.2017.161034","article-title":"Predictive value of hepatitis B core-related antigen (HBcrAg) during the natural history of hepatitis B virus infection","volume":"63","author":"Gou","year":"2017","journal-title":"Clin Lab."},{"key":"B31","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s00432-007-0224-y","article-title":"Prediction of chronic hepatitis B, liver cirrhosis and hepatocellular carcinoma by SELDI-based serum decision tree classification","volume":"133","author":"Cui","year":"2007","journal-title":"J Cancer Res Clin Oncol."}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2022.1037508\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T10:00:09Z","timestamp":1666951209000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2022.1037508\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,28]]},"references-count":31,"alternative-id":["10.3389\/fpubh.2022.1037508"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2022.1037508","relation":{},"ISSN":["2296-2565"],"issn-type":[{"type":"electronic","value":"2296-2565"}],"subject":[],"published":{"date-parts":[[2022,10,28]]},"article-number":"1037508"}}